Adaptimmune Therapeutics PLC Sponsored ADR Forecast, price target & analysts
Adaptimmune Therapeutics PLC Sponsored ADR Target price 2025 - Analyst rating & recommendation
Adaptimmune Therapeutics PLC Sponsored ADR Classifications & Recommendation:
Adaptimmune Therapeutics PLC Sponsored ADR Price Target
| Target Price | $1.59 |
| Price | $0.28 |
| Potential |
457.09%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Adaptimmune Therapeutics PLC Sponsored ADR 2026 .
The average Adaptimmune Therapeutics PLC Sponsored ADR target price is $1.59.
This is
457.09%
register free of charge
$3.00
953.00%
register free of charge
$0.46
61.46%
register free of charge
|
|
| A rating was issued by 8 analysts: 4 Analysts recommend Adaptimmune Therapeutics PLC Sponsored ADR to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adaptimmune Therapeutics PLC Sponsored ADR stock has an average upside potential 2026 of
457.09%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 178.03 | 49.33 |
| 195.34% | 72.29% | |
| EBITDA Margin | -23.13% | -225.03% |
| 88.46% | 872.85% | |
| Net Margin | -39.77% | -710.92% |
| 78.94% | 1,687.39% |
6 Analysts have issued a sales forecast Adaptimmune Therapeutics PLC Sponsored ADR 2025 . The average Adaptimmune Therapeutics PLC Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Adaptimmune Therapeutics PLC Sponsored ADR 2025 . The average Adaptimmune Therapeutics PLC Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Adaptimmune Therapeutics PLC Sponsored ADR Analysts have issued a net profit forecast 2025. The average Adaptimmune Therapeutics PLC Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.05 | -0.23 |
| 44.44% | 360.00% | |
| P/E | negative | |
| EV/Sales | 0.84 |
3 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast for earnings per share. The average Adaptimmune Therapeutics PLC Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Adaptimmune Therapeutics PLC Sponsored ADR...
Current Adaptimmune Therapeutics PLC Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | May 14 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Nov 27 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Nov 27 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
